MRI for Understanding Glioblastoma Biology
This study is looking at how Magnetic Resonance Imaging (MRI) can help us better understand glioblastoma, a type of brain tumor that can be removed by surgery. Researchers want to see if specific measurements from MRI scans can tell us more about the tumor's biology, specifically about certain proteins (like Decorin, or DCN) and genetic material (DNA and RNA) within the tumor. This could lead to better ways to understand and treat glioblastoma. You might be able to join if you are over 18 and have newly diagnosed or recurrent glioblastoma that can be surgically removed. The study aims to enroll 50 participants, but its current recruitment status is unclear.
- Study design
- This is an interventional study with a planned enrollment of 50 participants. It is not specified if it is randomized or blinded.
- What's involved
- You would undergo one MRI scan before surgery, and researchers would collect tissue samples from your tumor during surgery. Your medical chart would also be reviewed.
- Compensation
- Not stated in the trial record.
- Follow-up
- Researchers will look at certain measurements for up to 5 years after you join the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Benjamin M Ellingson · PRINCIPAL_INVESTIGATOR · UCLA / Jonsson Comprehensive Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Decorin (DCN) expressionUp to 5 years
Will use a two-sided t-test to compare DCN immunohistochemistry (IHC), in-situ hybridization (ISH), and ribonucleic acid (RNA) sequencing positivity between low apparent diffusion coefficient (ADCL) \< 1.24 um\^2/ms and ADCL \> 1.24 um2/ms groups.
- DCN expression correlated to ADCLUp to 5 years
Will assess whether DCN IHC, ISH, and RNA expression within the tumor is linearly correlated with continuous values of ADCL. To test this, will examine Pearson's correlation coefficient (R\^2) and test whether the slope of the linear regression line is significantly different from zero. After purification, will also quantify the particular genotype or cell states represented by tumor cells for each ADCL phenotype.
- Incidence of tumors with high diffusion measurements among MES-like cellsUp to 5 years
Will assess whether MES-like cells have higher frequency of incidence of ADCL \> 1.24 um\^2/ms compared to other genotypes. To test this, will use a chi-squared goodness of fit test to assess the frequency of observations and an analysis of variance (ANOVA) to look at DCN protein, deoxyribonucleic acid (DNA), and RNA expression between genotypes.
- DCN expression among Mesenchymal-Like (MES-like) cellsUp to 5 years
Will assess whether MES-like cells have higher overall DCN expression levels compared to other genotypes. To test this, will use a chi-squared goodness of fit test to assess the frequency of observations and an ANOVA to look at DCN protein, DNA, and RNA expression between genotypes.